Goldman Sachs’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,200
| Closed | -$26.6K | – | 5276 |
|
|
2023
Q1 | $26.6K | Buy |
2,200
+900
| +69% | +$10.9K | ﹤0.01% | 4854 |
|
|
2022
Q4 | $5.92K | Sell |
1,300
-25
| -2% | -$114 | ﹤0.01% | 4993 |
|
|
2022
Q3 | $9K | Buy |
1,325
+15
| +1% | +$102 | ﹤0.01% | 5272 |
|
|
2022
Q2 | $14K | Buy |
1,310
+144
| +12% | +$1.54K | ﹤0.01% | 5478 |
|
|
2022
Q1 | $22K | Sell |
1,166
-3,105
| -73% | -$58.6K | ﹤0.01% | 5598 |
|
|
2021
Q4 | $154K | Buy |
4,271
+589
| +16% | +$21.2K | ﹤0.01% | 5092 |
|
|
2021
Q3 | $270K | Buy |
3,682
+1,101
| +43% | +$80.7K | ﹤0.01% | 4721 |
|
|
2021
Q2 | $360K | Buy |
2,581
+1,070
| +71% | +$149K | ﹤0.01% | 4607 |
|
|
2021
Q1 | $439K | Sell |
1,511
-1,181
| -44% | -$343K | ﹤0.01% | 4445 |
|
|
2020
Q4 | $1.68M | Buy |
+2,692
| New | +$1.68M | ﹤0.01% | 3161 |
|